Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Curr Med Sci. 2023 Dec;43(6):1221-1228. doi: 10.1007/s11596-023-2822-6. Epub 2023 Dec 28.
This study aimed to investigate the safety and efficacy of endovascular aortic repair (EVAR) for the treatment of an abdominal aortic aneurysm (AAA) with a hostile neck anatomy (HNA).
From January 1, 2015 to December 31, 2019, a total of 259 patients diagnosed with an AAA who underwent EVAR were recruited into this study. Based on the morphological characteristics of the proximal neck anatomy, the patients were divided into the HNA group and the friendly neck anatomy (FNA) group. The patients were followed up for up to 4 years.
The average follow-up time was 1056.1±535.5 days. Type I endoleak occurred in 4 patients in the HNA group, and 2 patients in the FNA group. Neither death nor intraoperative switch to open repair occurred in either group. The time of the operation was significantly longer in the HNA group (FNA vs. HNA, 99.2±51.1 min vs. 117.5±63.8 min, P=0.011). There were no significant differences in short-term clinical success rate (P=0.228) or midterm clinical success rate (P=0.889) between the two groups. The overall mortality rate was 10.4%, and Kaplan-Meier survival analysis indicated that the two groups had similar cumulative survival rates at the end of the follow-up period (P=0.889).
EVAR was feasible and safe in patients with an AAA with a proximal HNA. The early and midterm results were promising; however, further studies are needed to verify the long-term effectiveness of EVAR.
本研究旨在探讨血管内主动脉修复术(EVAR)治疗具有不利颈部解剖结构(HNA)的腹主动脉瘤(AAA)的安全性和有效性。
本研究共纳入 2015 年 1 月 1 日至 2019 年 12 月 31 日期间 259 例接受 EVAR 治疗的 AAA 患者。根据近端颈部解剖结构的形态学特征,将患者分为 HNA 组和友好颈部解剖结构(FNA)组。对患者进行最长 4 年的随访。
平均随访时间为 1056.1±535.5 天。HNA 组有 4 例患者发生 I 型内漏,FNA 组有 2 例。两组均无死亡或术中转为开放修复。HNA 组的手术时间明显更长(FNA 组 vs. HNA 组,99.2±51.1min vs. 117.5±63.8min,P=0.011)。两组的短期临床成功率(P=0.228)和中期临床成功率(P=0.889)无显著差异。总的死亡率为 10.4%,Kaplan-Meier 生存分析表明,两组在随访期末的累积生存率相似(P=0.889)。
对于具有近端 HNA 的 AAA 患者,EVAR 是可行且安全的。早期和中期结果令人鼓舞;然而,需要进一步的研究来验证 EVAR 的长期疗效。